(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women- Instructions to Augment the Presentation of Your Kona SUV
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- ‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Genetic study identifies earliest-known dog, dating to 15,800 years ago
- Here are 10 stores where you can get a free Thanksgiving turkey
- Manual for Picking Coastline Travel
- Grasping the Basics of Business Land Regulation
